| Specialist input | Percentage of respondents |
|---|---|
| Genetic testing and counseling in oncology | 62% |
| Molecular/biomarker testing in oncology (Pathologists input) | 58% |
| Molecular/biomarker testing in oncology (Oncologists input) | 57% |
| Next-generation sequencing in oncology | 44% |
| Advance care planning and palliative care | 39% |
| Survivorship planning care | 20% |
The chart is not accessible to screen readers. Please switch to the table view to access the data.
Loading statistic...
Download
Source
Source
Release date
May 2019
More information
Region
United States
Survey time period
November and December 2018
Number of respondents
97 managed care organizations (MCOs)
Method of interview
Online survey
Supplementary notes
The survey in total includes data from following groups: managed care organizations (MCOs), specialty pharmacies (SPs), oncologists, oncology practice managers (OPMs), employers that sponsor health benefits.
Citation formats
